(Q42981730)

English

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

scientific article published on 17 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. (English)

1 reference

Europe PubMed Central

12 November 2017

Japanese encephalitis virus

0 references

1 reference

based on heuristic

inferred from title

Japanese encephalitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tick-borne encephalitis virus

object named as

tick-borne encephalitis virus

1 reference

based on heuristic

inferred from title

Herwig Kollaritsch

4

1 reference

Europe PubMed Central

12 November 2017

6

object named as

Bernd Jilma

1 reference

Europe PubMed Central

12 November 2017

author name string

Elisabeth Schuller

1

1 reference

Europe PubMed Central

12 November 2017

Christoph S Klade

2

1 reference

Europe PubMed Central

12 November 2017

Franz X Heinz

3

1 reference

Europe PubMed Central

12 November 2017

Pamela Rendi-Wagner

5

1 reference

Europe PubMed Central

12 November 2017

Erich Tauber

7

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

17 September 2008

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

26

1 reference

Europe PubMed Central

12 November 2017

48

1 reference

Europe PubMed Central

12 November 2017

6151-6156

1 reference

Europe PubMed Central

12 November 2017

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Japanese encephalitis: development of new candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Further experience with Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

TBE vaccination and the Austrian experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Field effectiveness of vaccination against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Protection against Japanese encephalitis by inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Studies on serological cross-reaction in sequential flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Atypical antibody responses in dengue vaccine recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Pathogenesis of dengue: challenges to molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Antibody-dependent enhancement of tick-borne encephalitis virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.056

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.08.056

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981730&oldid=1608938310"